Jeena Sikho Lifecare Publishes 6 Case Studies on Ayurvedic Treatments
Jeena Sikho Lifecare Limited has published six case studies and reports in the International Journal of Advanced Research and the Journal of Ayurveda and Integrated Medical Sciences. The publications highlight the company's commitment to Ayurvedic research and evidence-based clinical practices, covering treatments for liver disease, kidney disease, and diabetes.
The publication of case studies is a positive step for the company's research profile but is unlikely to have a significant immediate impact on its financial performance or stock price. It serves as a routine update on ongoing R&D activities.
The announcement details the publication of case studies, which is a routine update on the company's research and development efforts. While positive in nature, it does not directly impact financial performance or market position in a significant way that would warrant a 'POSITIVE' sentiment.
Jeena Sikho Lifecare Limited has announced the publication of six case studies and case reports authored by medical professionals associated with the company, including its Managing Director, senior consultants, and Ayurvedic experts.
These publications have appeared in the "International Journal of Advanced Research (IJAR)" and the "Journal of Ayurveda and Integrated Medical Sciences (JAIMS)". The company states that these publications underscore its dedication to Ayurvedic research and evidence-based clinical practices.
The published works include studies on the treatment of fatty liver with associated dyslipidemia, effectiveness of Shodhana and Shamana therapies in Udar Vikar, a case report on reversing chronic kidney disease through Ayurvedic interventions, Ayurvedic methods to revert Type 2 Diabetes Mellitus, the therapeutic role of Ayurveda in chronic liver disease, and the efficacy of Ayurvedic management in Diabetes Mellitus Type II.
Links to all the case studies and reports are available, and the information is also accessible on the company's website, www.jeenasikho.com. The announcement was made on 23rd February 2026.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.